Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 206

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 206
---
iod as described under “ Principal Shareholders — Restrictions on Transfers of Founder Shares and Private Units.” We will bear the expenses incurred in connection with the filing of any such registration statements.

131 Certain relationships and related party transactions On June 17, 2024, we issued to our sponsor an aggregate of 22,361,111 ordinary shares for an aggregate purchase price of $35,000, or approximately $0.0016 per share. On November6, 2024, the sponsor surrendered and forfeited 12,503,968 ordinary shares to us for no consideration, following which the sponsor holds 9,857,143 founder shares. Our sponsor or our initial shareholders will own 30% of our issued and outstanding ordinary shares after this offering (not including the private units and the representative shares and assuming they do not purchase any units in this offering or in the after -market). Up to 1,285,714 founder shares are subject to surrender and forfeiture by our initial shareholders depending on the extent to which the underwriters’ over -allotmentoption is exercised. Our sponsor has committed to purchase an aggregate of 400,000 private units (or 430,000 private units if the underwriters’ option to purchase additional units is exercised in full) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters’ option to purchase additional units is exercised in full) in a private placement that will occur simultaneously with the closing of this offering. Each private unit will consist of one ordinary share and one right to receive one -eighth(1/8) of an ordinary share upon the consummation of an initial business combination. The private units are identical to the units sold in this offering, subject to certain limited exceptions as described in this prospectus. The non -managingsponsor investors have indicated an interest to indirectly purchase, through the purchase of non -managingsponsor membership interests, an aggregate of 50,000 of the 400,000 private units (or 430,000 private placement units if the underwriters’ over -allotmentoption is exercised in full) being purchased by our sponsor at a price of $10.00 per unit ($500,000 in the aggregate) in a private placement that will close simultaneously with the closing of this offering. Subject to each non -managingsponsor investor purchasing, through the sponsor, the private placement units allocated to it in